CVSD Stock Overview
Provides health solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
CVS Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.05 |
| 52 Week High | US$68.12 |
| 52 Week Low | US$51.05 |
| Beta | 0.54 |
| 11 Month Change | 1.96% |
| 3 Month Change | 1.96% |
| 1 Year Change | -17.49% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVSD | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -0.08% | -2.2% | -0.4% |
| 1Y | -17.5% | -23.8% | 5.6% |
Return vs Industry: CVSD exceeded the UK Healthcare industry which returned -23.8% over the past year.
Return vs Market: CVSD underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| CVSD volatility | |
|---|---|
| CVSD Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CVSD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine CVSD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 259,500 | J. Joyner | www.cvshealth.com |
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
CVS Health Corporation Fundamentals Summary
| CVSD fundamental statistics | |
|---|---|
| Market cap | €63.58b |
| Earnings (TTM) | €4.76b |
| Revenue (TTM) | €348.85b |
13.3x
P/E Ratio0.2x
P/S RatioIs CVSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVSD income statement (TTM) | |
|---|---|
| Revenue | US$367.25b |
| Cost of Revenue | US$316.53b |
| Gross Profit | US$50.71b |
| Other Expenses | US$45.70b |
| Earnings | US$5.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.99 |
| Gross Margin | 13.81% |
| Net Profit Margin | 1.37% |
| Debt/Equity Ratio | 85.4% |
How did CVSD perform over the long term?
See historical performance and comparison